Home

Message from our CEO

812x408 Jeffrey Leiden_0.png

Jeffrey Leiden, Chairman, President and CEO

Events & Presentations

Latest Press Releases

Date Title and Summary
Toggle Summary Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines
-Eligible patients in Wales will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:
Toggle Summary Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines
-Eligible patients in Northern Ireland will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 12, 2019-- Vertex Pharmaceuticals Incorporated
Toggle Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 12
BOSTON --(BUSINESS WIRE)--Nov. 7, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET . Management’s remarks will be available live through Vertex’s website at

Copyright West LLC. Minimum 15 minutes delayed.